Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,016 questions · 2,067 findings · 222 reviews · Headline outcomes only

No studies found 471 · 22.8%GRADE not reported 108 · 5.2%Very low 570 · 27.6%Low 458 · 22.2%Moderate 363 · 17.6%High 97 · 4.7%

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Adverse events1 · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Congestive heart failure · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Septic embolism1 · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Need for cardiac surgical interventions · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Uncontrolled infection1 · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus

The review found no eligible studies for this question.

1 finding from 1 review

Lipopeptide antibiotic (daptomycin) vs aminoglycoside (low‐dose gentamicin) plus anti‐staphylococcal penicillin (nafcillin, oxacillin or flucloxacillin) or glycopeptide antibiotic (vancomycin)

Cure · people with endocarditis caused by Staphylococcus aureus

It is very uncertain whether lipopeptide antibiotic (daptomycin) changes cure compared with aminoglycoside (low‐dose gentamicin) plus antistaphylococcal… (very low certainty).

1 finding from 1 review

Antibiotics vs placebo

Death at 6 months · adults with renal vasculitis for maintenance therapy

Antibiotics showed no clear difference in death at 6 months compared with placebo (low certainty).

1 finding from 1 review

Antibiotics vs placebo

Remission · adults with renal vasculitis for maintenance therapy

Antibiotics showed no clear difference in remission at one year compared with placebo (low certainty).

1 finding from 1 review

Antibiotics vs placebo

Discontinuation of medication due to adverse events · adults with renal vasculitis for maintenance therapy

Antibiotics showed no clear difference in adverse events causing study drug discontinuation compared with placebo (low certainty).

1 finding from 1 review